Kimyrsa — Compare Prices at US & Canada Pharmacies

Kimyrsa is a brand of oritavancin — the same active ingredient sold as Orbactiv, but formulated for a shorter, 1-hour infusion rather than Orbactiv's 3-hour infusion. Both are single-dose lipoglycopeptide antibiotics: one 1,200 mg IV infusion treats an acute bacterial skin and skin-structure infection outright, with no follow-up doses needed, because oritavancin's extremely long half-life (roughly 245 hours) keeps therapeutic drug levels in tissue for weeks after the single dose. That's the same one-and-done niche occupied by dalbavancin (Dalvance) — these long-acting lipoglycopeptides let clinicians treat serious skin infections, including those caused by MRSA, without admitting a patient for days of IV vancomycin or committing them to daily infusion visits.

Oritavancin's most clinically important quirk is a lab interference problem, not a typical drug interaction: it artificially and falsely elevates coagulation test results — activated partial thromboplastin time (aPTT) can stay falsely elevated for up to 5 days, and PT/INR can be affected for up to 12 hours. Because of this, intravenous unfractionated heparin is contraindicated for 5 days after a Kimyrsa dose, since a falsely reassuring aPTT could mask inadequate anticoagulation or bleeding risk. Anyone caring for the patient afterward — including a different hospital or clinic — needs to know a long-acting lipoglycopeptide was given, since the coagulation test distortion can outlast the visit where it was administered.

Like other agents reserved for resistant Gram-positive infections, Kimyrsa sits in WHO's Reserve AWaRe category, meant for infections where standard options are inadequate rather than routine first-line use.

Contraindications

4 CONTRAINDICATIONS Use of intravenous unfractionated heparin sodium is contraindicated for 120 hours (5 days) after KIMYRSA administration. ( 4.1 , 5.1 ) Known hypersensitivity to oritavancin products. ( 4.2 , 5.2 ) 4.1 Intravenous Unfractionated Heparin Sodium Use of intravenous unfractionated heparin sodium is contraindicated for 120 hours (5 days) after KIMYRSA administration because the activated partial thromboplastin time (aPTT) test results may remain falsely elevated for up to 120…

Pregnancy & breastfeeding

8.1 Pregnancy Risk Summary There are no available data on KIMYRSA use in pregnant women to evaluate for a drug- associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. In animal reproduction studies, no effects on embryo-fetal development or survival were observed in pregnant rats or rabbits treated at the highest doses throughout organogenesis with intravenous oritavancin, at doses equivalent to 25% of the single clinical dose of 1,200 mg (see Data ) .